DaVita
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 70K
- Market Cap
- -
- Introduction
DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.
Senseonics' Eversense 365 CGM System Receives FDA Clearance for One-Year Use
• Senseonics and Ascensia Diabetes Care secured FDA clearance for Eversense 365, a next-generation continuous glucose monitoring (CGM) system, for adults with type 1 and type 2 diabetes.
• Eversense 365 is the first iCGM system that can integrate with compatible medical devices, including insulin pumps, as part of an automated insulin delivery system.
• The Eversense 365 system offers continuous glucose monitoring for up to one year with a single sensor, reducing the frequency of sensor replacements compared to short-term CGMs.
• Ascensia plans to launch Eversense 365 in the U.S. in the fourth quarter of 2024, aiming to facilitate broad access for users.
© Copyright 2025. All Rights Reserved by MedPath